Since supra-normal circulating lysosomal enzymatic levels are required for normalization of aortic pathology in animal models [27,28], therapies targeting MPS cardiovascular disease must focus on maximizing enzymatic uptake in vascular intima/media, or abrogating vascular intraparenchymal inflammation, cellular proliferation, and disruption of elastin laminae. Here, ELN is linked to cardiovascular disorder.